SuperworthAnika Therapeutics profit margin ANIK
Gross, operating and net profit as a share of revenue over the last twelve months, from 2011.
- Net margin, 12 months
- −3.1%
- Operating margin, 12 months
- −4.2%
- Net margin on a year earlier
- +49.8 pts
- Peer median
- 6.5%
Over the twelve months to Jun 30, 2026, Anika Therapeutics kept −3.1% of its revenue as net profit, with an operating margin of −4.2% and a gross margin of 62.2%.
Five years earlier its net margin was −9.3%.
The median for 10 medical instruments and supplies stocks of a similar size is 6.5%.
Profit margin over time
Fiscal year by fiscal year
| Fiscal year | Net margin | Operating margin | Gross margin |
|---|---|---|---|
| FY2025 | −9.6% | −9.8% | 56.6% |
| FY2024 | −47.0% | −4.3% | 63.4% |
| FY2023 | −49.6% | −52.6% | 61.9% |
| FY2022 | −9.5% | −12.4% | 59.9% |
| FY2021 | 2.8% | 1.8% | 56.1% |
| FY2020 | −18.4% | −21.7% | 52.9% |
| FY2019 | 23.7% | 29.9% | 74.9% |
| FY2018 | 17.7% | 20.6% | 70.4% |
| FY2017 | 28.1% | 40.3% | 75.9% |
| FY2016 | 31.5% | 49.0% | 76.8% |
| FY2015 | 33.1% | 51.8% | 77.4% |
| FY2014 | 36.3% | 58.2% | 80.2% |
| FY2013 | 27.4% | 43.4% | 69.7% |
| FY2012 | 16.5% | 27.6% | 59.4% |
| FY2011 | 13.1% | 21.6% | 58.7% |
Quarter by quarter
| Quarter | Ended | Net margin, 12 months | Change on a year | Operating margin |
|---|---|---|---|---|
| Q2 FY26 | −3.1% | +49.8 pts | −4.2% | |
| Q1 FY26 | −9.5% | +39.0 pts | −10.5% | |
| Q4 FY25 | −9.6% | +37.4 pts | −9.8% | |
| Q3 FY25 | −29.3% | +44.4 pts | −11.0% | |
| Q2 FY25 | −52.9% | −1.5 pts | −8.1% | |
| Q1 FY25 | −48.5% | +0.2 pts | −5.9% | |
| Q4 FY24 | −47.0% | +2.6 pts | −4.3% | |
| Q3 FY24 | −73.7% | −58.7 pts | −51.5% | |
| Q2 FY24 | −51.4% | −37.8 pts | −52.6% | |
| Q1 FY24 | −48.7% | −34.6 pts | −49.2% | |
| Q4 FY23 | −49.6% | −40.1 pts | −52.6% | |
| Q3 FY23 | −15.0% | −4.7 pts | −18.7% |
Against its peers
Companies in Medical - Instruments & Supplies nearest Anika Therapeutics' size, closest first, today.
| Company | Profit margin |
|---|---|
| ANIKAnika Therapeutics | −3.1% |
| INFUInfuSystem | 6.0% |
| UTMDUtah Medical Products | 29.0% |
| EMBCEmbecta | 8.6% |
| PDEXPro DEX | 17.6% |
| TCMDTactile Systems Technology | 7.1% |
| MDXGMimedx | 1.8% |
| MOVMovado | 6.0% |
| KEQUKewaunee Scientific | 3.0% |
| IRMDIradimed | 26.7% |
| STAAStaar Surgical | 1.1% |
| Peer median | 6.5% |
Where Anika Therapeutics ranks
What the profit margin tells you
Profit as a share of revenue at three levels: gross (after making the product), operating (after running the business) and net (after everything, including tax and interest).
Compare within an industry. 10% is superb for a retailer and poor for a software company.
More on Anika Therapeutics
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.